Loading...
Medicare Part D: Drug Pricing and Manufacturer Windfalls
House Committee on Oversight and Government Reform
House Committee on Oversight and Government Reform
Abstract
The House Committee on Oversight and Government Reform compares drug prices under the Medicare Part D program with those under traditional Medicaid, revealing that Medicare Part D pays on average 30% more for drugs than Medicaid. The prices paid for drugs under Medicare Part D are found to be significantly higher than those paid by Medicaid, leading to a windfall of over $3.7 billion for drug manufacturers in the first two years of the Medicare Part D program. The report focuses on the costs to taxpayers for providing drug coverage to six million "dual eligible" beneficiaries, who qualify for both Medicare and Medicaid.
Date
2008-07-24
Document Type
House Majority Staff Report
Serial Number
Document Length
15 pages
Congress
110
Relation
DOI
Keywords
Staff Reports
PAP Major Code
3: Health
PAP Minor Code
335: Prescription Drug Coverage and Costs
Related Hearings
Press Releases and Contextual Information
https://web.archive.org/web/20090101101402/http://oversight.house.gov/story.asp?id=2103